PCOS has been officially renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This landmark shift in women’s health matters for your hormones and overall wellbeing.
For decades, millions of women have navigated a condition labeled "Polycystic Ovarian Syndrome" (PCOS), a name that often led to confusion, stigma, and delayed care. As of May 2026, a global consensus published in The Lancet has officially renamed this condition to Polyendocrine Metabolic Ovarian Syndrome (PMOS).
This isn't just a matter of semantics. It is a profound redefinition that finally acknowledges the complex, multisystem reality of what so many women experience every day. In my practice, I've always said that "normal isn't always normal," and this name change is the medical community finally catching up to that truth. It moves us away from a narrow focus on "cysts" and toward a comprehensive understanding of your metabolic and hormonal health.
The PMOS Redefinition: A Multisystem Shift
For too long, the "ovarian" focus of PCOS made it seem like a primarily gynaecological or fertility-related problem. The transition to Polyendocrine Metabolic Ovarian Syndrome (PMOS) recognizes that the condition impacts your entire body, from your metabolism and cardiovascular system to your skin and mental health.
This new framework is built on three core pillars:
Polyendocrine: Highlights the interacting hormonal disturbances across multiple glands, not just the ovaries.
Metabolic: Emphasizes the central role of insulin resistance and its long-term risks for type 2 diabetes and heart disease.
Ovarian: Acknowledges the reproductive component while placing it within a larger systemic context.
As Dr. Melanie Cree, a pediatric endocrinologist at CU Anschutz, notes:
"Renaming this condition is more than semantics; it’s about finally recognizing the full reality of what patients experience. For too long, the narrow definition of PCOS has overlooked its metabolic and hormonal complexity."
Dr. Melanie Cree, pediatric endocrinologist at CU Anschutz
Why "Polycystic" Was A Misleading Label
One of the biggest hurdles for patients was the term "polycystic" itself. Extensive research has shown that there is no actual increase in "abnormal cysts" in women with this condition. Instead, what are seen on ultrasound are often arrested follicles (or immature follicles), a sign of hormonal imbalance, not a disease of the ovaries themselves.
The old name inadvertently normalized a limited perspective: if you didn't have visible cysts, you were often told your labs were "normal" and your symptoms were dismissed. This led to diagnostic delays for up to 70% of individuals. By removing the requirement for cysts, the PMOS designation allows for earlier and more accurate identification of the syndrome's metabolic drivers.
The Metabolic Engine: Understanding The Drivers
At the heart of PMOS is a metabolic engine driven by insulin resistance. This metabolic hurdle affects many women with the condition, regardless of their body mass index (BMI). It is the "upstream" driver that triggers the excess production of androgens (male hormones) and chronic low-grade inflammation.
By reframing the condition as Polyendocrine Metabolic, we shift the focus of care:
Targeting Insulin: Improving how your body processes sugar to lower androgen levels naturally.
Reducing Inflammation: Calming the immune response to restore cycle regularity and improve mood.
Balancing Hormones: Addressing the complex interplay between your ovaries, adrenals, and thyroid (the OAT axis).
This shift is grounded in the largest-ever medical renaming survey, which gathered over 22,000 responses from patients and clinicians who found the previous name stigmatizing and confusing.
Clinical Implications: A New Standard of Care
The move to PMOS isn't just about changing the header on your medical records. It sets a new standard for how healthcare providers, including obstetricians, gynecologists, and naturopathic doctors approach your care. The goal is to move from reactive symptom management to proactive, holistic health advocacy.
This new standard of care emphasizes:
Earlier Diagnosis: Recognizing metabolic markers before reproductive symptoms become debilitating.
Comprehensive Testing: Moving beyond TSH and basic glucose to include full hormone panels and insulin sensitivity markers.
Holistic Management: Addressing the psychological impact and long-term cardiometabolic health alongside cycle regularity.
Try Dr. Kathy Nguyen
If you've been struggling with symptoms like irregular periods, persistent acne, thinning hair, or a mind that feels trapped in a fog, but have been told your labs are "normal,” it's time for a deeper look.
As a Naturopath in Ontario, I focus on comprehensive hormone testing and personalized treatment plans that honour the complexity of PMOS. You can book a free 15-minute e-consult to learn more about your options.
Frequently asked questions
What does PMOS stand for?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new clinically accurate name for what was previously known as Polycystic Ovary Syndrome (PCOS).
Why did the name change from PCOS to PMOS?
The name changed because 'polycystic' was inaccurate. Many patients don't have cysts and it focused too narrowly on the ovaries. The new name reflects that it is a multisystem metabolic and endocrine disorder.
Do I need to have cysts to be diagnosed with PMOS?
No. One of the main reasons for the name change was to clarify that ovarian cysts are not a requirement for diagnosis. PMOS is identified through a combination of hormonal and metabolic markers.
How common is PMOS?
PMOS is very common, affecting approximately 1 in 8 women worldwide. This equals more than 170 million individuals globally navigating its metabolic and hormonal effects.
Will my current PCOS treatment change with the new name?
While your diagnosis name is updated, the focus of care will shift even more toward addressing root causes like insulin resistance and systemic inflammation, providing a more holistic approach to your health.